Ironwood Pharmaceuticals
↗Boston, USA
Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for patients. The company is best known for its flagship product, LINZESS (linaclotide), which is a market leader in the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
In recent years, Ironwood has expanded its strategic focus to include rare diseases, notably through the 2023 acquisition of VectivBio. This move added apraglutide, a Phase 3 GLP-2 analog for Short Bowel Syndrome, to its pipeline. Despite recent regulatory hurdles, the company remains a central player in the GI therapeutic space, leveraging strong commercial partnerships with AbbVie and AstraZeneca.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$296M (2025)
Founded:1998
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$652.8M
Investors:Venrock, Ridgeback Capital Management, Athyrium Capital Management
STOCK
Exchange:NASDAQ
Ticker:IRWD
Market Cap:$558M
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (LINZESS)
Modalities:Small molecule, Peptides
Active Trials:5
Trial Phases:Phase 1: 1 | Phase 2: 2 | Phase 3: 1 | Phase 4: 1
FDA Approvals:2
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:VectivBio AG
Key Partnerships:AbbVie (U.S. LINZESS collaboration), AstraZeneca (China), Astellas (Japan)
COMPETITION
Position:Leader in IBS-C market; Challenger in Rare GI diseases.
Competitors:Ardelyx, Phathom Pharmaceuticals, Takeda, Bausch Health
LEADERSHIP
Key Executives:
Thomas McCourt - CEO
Michael Shetzline - Chief Medical Officer
Jeff Ruberti - CFO
Scientific Founders:Peter Hecht, Brian Cali, Todd Milne
Board Members:Thomas McCourt, Julie McHugh, Marsha Fanucci
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ironwood Pharmaceuticals. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.